| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/14/2023 | 494.06% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 11/06/2023 | 494.06% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 08/15/2023 | 395.05% | JMP Securities | → $5 | Reiterates | Market Outperform → Market Outperform |
| 08/15/2023 | 494.06% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 08/15/2023 | 296.04% | Needham | → $4 | Reiterates | Buy → Buy |
| 07/19/2023 | 494.06% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 07/12/2023 | 395.05% | JMP Securities | → $5 | Reiterates | Market Outperform → Market Outperform |
| 07/10/2023 | 494.06% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 06/14/2023 | 494.06% | JonesTrading | → $6 | Initiates Coverage On | → Buy |
| 06/01/2023 | 494.06% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 05/12/2023 | 494.06% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 04/28/2023 | 494.06% | JMP Securities | → $6 | Reiterates | → Market Outperform |
| 04/20/2023 | 296.04% | Needham | → $4 | Reiterates | → Buy |
| 04/19/2023 | 494.06% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 03/10/2023 | 494.06% | JMP Securities | $7 → $6 | Maintains | Market Outperform |
| 03/10/2023 | 494.06% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 03/10/2023 | 296.04% | Needham | $5 → $4 | Maintains | Buy |
| 02/13/2023 | 593.07% | JMP Securities | → $7 | Reiterates | → Market Outperform |
| 02/03/2023 | 395.05% | Needham | → $5 | Reiterates | → Buy |
| 11/10/2022 | 692.08% | Stifel | → $8 | Upgrades | Hold → Buy |
| 11/10/2022 | 395.05% | Needham | → $5 | Upgrades | Hold → Buy |
| 11/10/2022 | 494.06% | HC Wainwright & Co. | $5 → $6 | Maintains | Buy |
| 08/10/2022 | 395.05% | HC Wainwright & Co. | $10 → $5 | Maintains | Buy |
| 03/11/2022 | 890.1% | JMP Securities | $11 → $10 | Maintains | Market Outperform |
| 07/29/2021 | 890.1% | HC Wainwright & Co. | → $10 | Initiates Coverage On | → Buy |
| 06/17/2021 | 1682.18% | Wedbush | $6 → $18 | Maintains | Outperform |
| 06/15/2021 | 791.09% | JMP Securities | $8 → $9 | Maintains | Market Outperform |
| 05/13/2020 | 692.08% | Roth Capital | → $8 | Initiates Coverage On | → Buy |
| 01/27/2020 | 395.05% | Wedbush | $3 → $5 | Maintains | Outperform |
What is the target price for Clearside Biomedical (CLSD)?
The latest price target for Clearside Biomedical (NASDAQ: CLSD) was reported by HC Wainwright & Co. on November 14, 2023. The analyst firm set a price target for $6.00 expecting CLSD to rise to within 12 months (a possible 494.06% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Clearside Biomedical (CLSD)?
The latest analyst rating for Clearside Biomedical (NASDAQ: CLSD) was provided by HC Wainwright & Co., and Clearside Biomedical reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Clearside Biomedical (CLSD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Clearside Biomedical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Clearside Biomedical was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.
Is the Analyst Rating Clearside Biomedical (CLSD) correct?
While ratings are subjective and will change, the latest Clearside Biomedical (CLSD) rating was a reiterated with a price target of $0.00 to $6.00. The current price Clearside Biomedical (CLSD) is trading at is $1.01, which is within the analyst's predicted range.